<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534299</url>
  </required_header>
  <id_info>
    <org_study_id>10031728DOC</org_study_id>
    <nct_id>NCT01534299</nct_id>
  </id_info>
  <brief_title>Global SYMPLICITY Registry (GSR) DEFINE</brief_title>
  <official_title>Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, single-arm, non-interventional and open-label registry.&#xD;
      The purpose of the registry is to document the long-term safety and effectiveness of renal&#xD;
      denervation in a real world patient population with hypertension GSR DEFINE is the&#xD;
      continuation of the Global SYMPLICITY Registry and collectively will enroll approximately&#xD;
      5000 patients with hypertension who undergo the renal denervation procedure, from over 300&#xD;
      sites worldwide. Subjects included in GSR DEFINE will be followed for a minimum of 1 year and&#xD;
      up to 5 years post-procedure. Patients with uncontrolled hypertension will be enrolled in&#xD;
      accordance with the inclusion criteria specified in the protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry will collect data prospectively on patients that receive renal denervation and&#xD;
      treatment will be applied according to the 'Intended Use' in the IFU. The treatment will be&#xD;
      performed according to routine hospital practice and no additional tests are required&#xD;
      specific to the registry. This registry will serve as a tool to collect clinical data in&#xD;
      order to expand the knowledge base of safety, effectiveness and functionality of the&#xD;
      Medtronic renal denervation system in a real world patient population.&#xD;
&#xD;
      The key measures collected for the patients will be inclusive of, but are not limited to,&#xD;
      blood pressure measurements, change in medications, eGFR changes (based on the MDRD formula)&#xD;
      and clinical data pertaining to hypertension .&#xD;
&#xD;
      The inclusion criteria for the registry includes:&#xD;
&#xD;
        -  Age ≥ 18 years or minimum age as required by local regulations&#xD;
&#xD;
        -  The patient is an acceptable candidate for renal denervation based upon the Instructions&#xD;
           For Use for the Medtronic renal denervation system. The procedure must be performed with&#xD;
           an initial use, market-released Medtronic renal denervation catheter.&#xD;
&#xD;
        -  The patient or legal representative has been informed of the nature of the registry has&#xD;
           consented to participate and authorized the collection and release of this medical&#xD;
           information by signing a consent form (&quot;Patient Informed Consent Form&quot; or &quot;Patient Data&#xD;
           Release Authorization Form&quot;)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BP Measurements</measure>
    <time_frame>6 months</time_frame>
    <description>Blood pressure changes from baseline (Office Setting and 24-hr Ambulatory measurements)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denervation Treatment</arm_group_label>
    <description>All patients treated with renal denervation procedure will be enrolled as part of this single arm registry</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Renal Denervation System</intervention_name>
    <description>The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.</description>
    <arm_group_label>Renal Denervation Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects undergoing renal denervation procedure for hypertension&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years or minimum age as required by local regulations&#xD;
&#xD;
          -  The patient is an acceptable candidate for renal denervation based upon the&#xD;
             Instructions For Use for the Medtronic renal denervation system. The procedure must be&#xD;
             performed with an initial use, market-released Medtronic renal denervation catheter.&#xD;
&#xD;
          -  The patient or legal representative has been informed of the nature of the registry&#xD;
             has consented to participate and authorized the collection and release of this medical&#xD;
             information by signing a consent form (&quot;Patient Informed Consent Form&quot; or &quot;Patient&#xD;
             Data Release Authorization Form&quot;)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Böhm, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Saarland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Mancia, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Gerardo Hospital, Monza, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>K. Wandrey</last_name>
    <email>rs.medtroniccardiovascularclinicaltrials@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <state>Saarlandes</state>
        <zip>D-66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Böhm, MD</last_name>
      <phone>(+49) 6841-1623372</phone>
      <email>michael.boehm@uniklinikum-saarland.de</email>
    </contact>
    <contact_backup>
      <last_name>Felix Mahfoud, MD</last_name>
      <phone>+49 6841 16 21346</phone>
      <email>felix.mahfoud@uniklinikum-saarland.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Böhm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

